In this study, we investigated the heterogeneity and the purity grade of three commercially
available plasma‐derived clotting factor VIII (FVIII) concentrates, which highly differ with
regard to purification strategies, relative concentrations of stabilizers (von Willebrand factor,
with or without albumin) and virus inactivation strategies (solvent/detergent and/or
heat/pasteurization treatments). Western blot analyses were used to evaluate product‐
specific variations from Emoclot®, Alphanate® and Haemate® both in the presence and …